New trends for osteoarthritis: Biomaterials, models and modeling

Seng Manivong (1, 2) , Aurélie Cullier (3) , Fabrice Audigié (4) , Xavier Banquy (2, 1) , Florina Moldovan (1, 2) , Magali Demoor (3) , V. Gaëlle Roullin (2, 1)

1 Centre de recherche du CHU Sainte-Justine / Research Center of the Sainte-Justine University Hospital [Montreal, Canada]
2 Faculté de Pharmacie [Montréal]
3 BIOTARGEN - Biologie, génétique et thérapies ostéoarticulaires et respiratoires
4 CIRALE - Centre d'Imagerie et de Recherche sur les Affections Locomotrices Equines - Center of Imaging and Research in Locomotor Affections on Equines ENVA

The burden of osteoarthritis (OA), one of the major causes of functional disabilities in humans and animals, continues to increase worldwide while no disease-modifying OA drugs (DMOADs) that either slow down or reverse disease progression have been made available. Here, we provide a brief overview of recent advances in: designing new OA drug delivery approaches, focusing on lubrication-based biomaterials and drug delivery systems, such as hydrogels, liposomes, dendrimers, micro- and nanoparticles; using either large (horse) or small (zebrafish) relevant animal models to evaluate new therapeutic strategies; and OA in vitro modeling, focusing on 3D (organoid) models of cartilage regarding the Replace, Reduce and Refine (3R) principle of animal experimentation.

Mots clés: biomaterials; drug delivery systems; horse; organoids; orthobiologics; osteoarthritis; zebrafish

Domaines: Biologie cellulaire

Seng Manivong, Aurélie Cullier, Fabrice Audigié, Xavier Banquy, Florina Moldovan, et al.. New trends for osteoarthritis: Biomaterials, models and modeling. Drug Discovery Today, 2023, 28 (3), pp.103488. ⟨10.1016/j.drudis.2023.103488⟩. ⟨hal-03975532⟩